quizartinib FLT3
Selected indexed studies
- Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. (Lancet, 2023) [PMID:37116523]
- Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML. (J Hematol Oncol, 2024) [PMID:39538314]
- FLT3 inhibitor quizartinib (AC220). (Leuk Lymphoma, 2019) [PMID:30997851]
_Worker-drafted node — pending editorial review._
Connections
quizartinib FLT3 is a side effect of
Sources
- Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. (2023) pubmed
- Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML. (2024) pubmed
- Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. (2019) pubmed
- FLT3 inhibitor quizartinib (AC220). (2019) pubmed
- Targeting FLT3 Mutations in Acute Myeloid Leukemia: The Role of Quizartinib in Precision Medicine. (2025) pubmed
- Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study. (2026) pubmed
- Quizartinib, the next FLT3 inhibitor. (2023) pubmed
- A review of FLT3 inhibitors in acute myeloid leukemia. (2022) pubmed
- Quizartinib in the treatment of FLT3-internal-tandem duplication-positive acute myeloid leukemia. (2019) pubmed
- Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia. (2014) pubmed